Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410902 · ClinicalTrials.gov registry record · Phase 3
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)
A Phase 3 study, sponsored by Curemark.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT02410902: Completed Phase 3 study, sponsored by Curemark.
NCT02410902 is a Phase 3 study that has completed, run by Curemark. The registered enrollment target is 190 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02410902, a Phase 3 study, has completed, sponsored by Curemark.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.
Primary Outcome
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale ra
Interventions
- DRUG PLACEBO
- DRUG CM-AT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2015-05-13 |
| Est. Completion | 2017-12-22 |
| Phase | Phase 3 |
What the finished NCT02410902 record still lists
NCT02410902 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT02410902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02410902 about?
NCT02410902 is a clinical study titled "A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)". The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.
What is the current status of trial NCT02410902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2015-05-13. Estimated completion is 2017-12-22.
What interventions are being tested in trial NCT02410902?
The interventions under investigation include: PLACEBO (DRUG), CM-AT (DRUG).
Who is sponsoring clinical trial NCT02410902?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02410902's enrollment target sits among peer trials
190 1402nd of 2000 higher than 593 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI